Physician profile
Eric D Schultz
NPI 1578774980
$10,645.22
in general payments reported to CMS, 2019-2025
36 companies · $1,754 in 2025
The $1,754 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $1,023 · 2021: $944 · 2022: $1,485 · 2023: $3,058 · 2024: $1,716 · 2025: $1,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,834 · Consulting Fee: $1,307 · Education: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,833.87 |
| Consulting Fee | $1,306.60 |
| Education | $387.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,228.76 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,826.81 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $1,258.68 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,036.97 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $656.28 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Csl Behring | $573.82 | 2019-2025 | Andembry, Hizentra, Haegarda |
| Biocryst US Sales Co., LLC | $500.29 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $383.85 | 2021-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Sanofi-Aventis U.S. LLC | $239.97 | 2022-2025 | |
| Alk-Abello, INC | $236.79 | 2019-2022 | |
| Pharming Healthcare, INC. | $214.92 | 2022-2025 | Ruconest |
| Genentech USA, INC. | $159.54 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $136.45 | 2019-2025 | |
| Kaleo, INC. | $125.04 | 2019-2023 | Auvi-Q |
| Grifols USA, LLC | $103.64 | 2019-2025 | Xembify |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adma Biomanufacturing LLC | $97.11 | 2020-2024 | |
| Lilly USA, LLC | $93.28 | 2024-2025 | Ebglyss |
| Amgen INC. | $93.24 | 2022-2024 | Tezspire |
| Ionis Pharmaceuticals, INC. | $77.05 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.04 | 2021 | |
| Incyte Corporation | $73.54 | 2022-2025 | Opzelura |
| Shire North American Group INC | $56.27 | 2019 | |
| Blueprint Medicines Corporation | $54.72 | 2023-2025 | Ayvakit |
| Optinose US, INC. | $52.44 | 2022-2023 | |
| Kedrion Biopharma, INC. | $48.34 | 2024-2025 | Albuked, Rhogam Ultra-Filtered Plus, Koate |
| Hospira, INC. | $34.58 | 2024-2025 | |
| Pfizer INC. | $31.30 | 2019-2025 | |
| Gc Biopharma USA, INC. | $27.45 | 2024 | Alyglo |
| Ars Pharmaceuticals Operations, INC. | $25.75 | 2025 | Neffy |
| Phadia US INC. | $20.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.59 | 2021 | |
| Mylan Specialty L.P. | $18.15 | 2023 | Yupelri |
| Horizon Therapeutics Plc | $17.38 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.02 | 2025 | Alvesco |
| Biocryst Pharmaceuticals, INC. | $17.00 | 2020 | |
| Hikma Pharmaceuticals USA | $15.30 | 2023 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.